Some cancers respond well to immunotherapy, a medication therapy that prompts the immune system to target tumours, although results against lung cancer have been conflicting.
Before World Cancer Day (4 February), a new study from the University of Southampton's Centre for Cancer Immunology demonstrated that altering how tightly an antibody attaches to a target could enhance cancer therapies.
The source of tumour cell resistance to immunotherapy was identified by a recent study that examined the pancreatic cancer tumour microenvironment, and novel therapeutic approaches were developed as a result.
According to MSD, Keytruda is the first cancer immunotherapy to be approved in India for the treatment of cervical cancer and the first immunotherapy to be approved as a first-line treatment for a significant sub-group of patients, who otherwise only had the option of chemotherapy as their t
Researchers revealed that Immunotherapies have improved the outcomes of many cancer patients, including those with melanoma. However, only a subset of patients benefit from these treatments.
A mechanism has been identified by researchers from the University of Michigan Rogel Cancer Center that explains why some patients' cancers grow in response to immunotherapy rather than shrinking.
Mount Sinai researchers have made two important discoveries about the mechanism by which bladder cancer cells foil attacks from the immune system. The research, published in Cancer Cell in September, could lead to a new therapeutic option for patients with these types of tumors.
Nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumours sensitive to a type of immunotherapy drug called a checkpoint inhibitor. This is according to a new study published in Cancer Immunology Research by researchers at
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells.
According to new research, mice with colorectal cancer who have tumours with high levels of ammonia have fewer T cells and are less responsive to immunotherapy. Ammonia, which is crucial for anti-tumor immunity, has been demonstrated to impede the proliferation and operation of T cells.
The findings of a new study suggest that nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumours sensitive to a type of immunotherapy drug called a checkpoint inhibitor.
Cancer-causing gene mutation KRAS, found in nearly 30 per cent of all human tumours, successfully shrunk tumours or stopped cancer growth in preclinical models of pancreatic cancer.